No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Established in 1989 and headquartered in Taipei City, Taiwan, BIONET Corp. is a global leader in umbilical cord blood preservation, serving clients across Taiwan and internationally. The company provides a comprehensive suite of stem cell banking services, encompassing the storage of general stem cells, mesenchymal stem cells, dental stem cells, adipose stem cells, and peripheral blood stem cells combined with immune cells. Beyond its core stem cell preservation, BIONET also conducts genetic testing services. Its product offerings further extend to anti-aging solutions leveraging stem cell technology, alongside its unique ANIKINE series. Additionally, the company is a pioneer in offering Exosome, an innovative cell-free therapeutic approach.
www.bionetcorp.comNo one on the platform currently holds 1784.TWO.
No tracked institution reports a position in 1784.TWO as of their last filing.
No one on the platform has traded 1784.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -0.9% | 3.6% | — | — | — | |
| Rev. Growth % | 1.2% | 8.9% | ||||
| Profit Margin % | 4.2% | 4.9% | ||||
| Free Cash Flow Margin % | 1.3% | 4.9% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +0.0% | $1.75 | $1.75–$1.75 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-07 | $0.31 | $0.39 | +25.8% |
| 2026-05-08 | $0.29 | $0.25 | -13.8% |
| 2026-03-04 | $0.68 | $0.29 | -57.4% |
| 2025-11-11 | $0.64 | $0.20 | -68.5% |
| 2025-08-07 | $0.57 | $0.23 | -59.6% |
| 2024-12-31 | $0.45 | $0.66 | +46.1% |
| 2024-09-30 | $0.42 | $0.23 | -45.3% |
| 2024-06-30 | $0.48 | $0.33 | -30.4% |
| +0.26% |
| $6.3B |
| — |
| 5312.TWOFormosa Optical Technology Co.,Ltd. | $90.30 | +0.67% | $5.4B | — |
| 6569.TWOOnyx Healthcare Inc. | $91.20 | +1.45% | $3.6B | — |
Source: Financial Modeling Prep · peers by sector/industry